Glioblastoma is a rapidly progressing disease with poor outcome, with a median overall survival (OS) of less than 15 months for patients with newly diagnosed glioblastoma. Though glioblastoma is a genetically diverse tumor type with multiple molecular subgroups, the current standard-of-care treatment of maximally safe surgical resection followed by temozolomide.
